Navigation Links
Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
Date:10/14/2008

s, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section in Item 1 of the Form 10-KSB we filed with the Securities and Exchange Commission on March 27, 2008. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Dr. Greg Leyer ... 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics in ... is an annual continuing education conference for health care professionals. ... included the topic of probiotics in health. Dr. Leyer spoke ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015  El ... abre hoy su llamada a nominaciones para 2015. Este ... ha hecho, o tiene el potencial para hacer, contribuciones ... nominaciones se aceptarán hasta el 15 de marzo de ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... , , , , , , , , ... NeoStem, Inc.,(NYSE Amex: NBS ) ("NeoStem" or the "Company"), an ... announced,today that it priced a public offering of 5,000,000 shares of ... the offering, after underwriting,discounts and commissions and expenses, will be approximately ...
... BOULDER, Colo. Physicists at JILA have for the first ... chemistry is possible at ultralow temperatures and that reaction ... rules of submicroscopic physics. The new results and ... Science, * will help scientists understand previously unknown aspects ...
... PARSIPPANY, N.J. , Feb. 11 ... M. Feingold , M.D., Ph.D., has been appointed Vice ... direction of the company,s Medical Affairs department and oversee ... responsible for collaborating with the company,s clinical research arm, ...
Cached Biology Technology:NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 2NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 3NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 4Seeing the quantum in chemistry: JILA scientists control chemical reactions of ultracold molecules 2Seeing the quantum in chemistry: JILA scientists control chemical reactions of ultracold molecules 3Seeing the quantum in chemistry: JILA scientists control chemical reactions of ultracold molecules 4Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs 2Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs 3
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced the ... report to their offering. ... in this market is the increasing demand for medical ... of patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... addition of the "Biometrics Market in India 2015-2019" ... major trend emerging in this market is the adoption ... than one characteristic of an individual for verification and ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... the male canary, the ability to sing a pitch-perfect song ... so does song quality and frequency. The hormone testosterone plays ... The Johns Hopkins University have found that introducing testosterone in ... ability to successfully attract and mate with a female through ...
... its recent synonymisation with Meloidogyne ulmi , a species ... clear that M. mali has been in the ... the authors suggest that M. mali was probably ... Elm Disease (DED) during which large numbers of Elm rootstocks ...
... Obesity rates in the United States increased from 14.5% ... in 2009-2010. It,s believed that one contributing factor to expanding ... that the ability to control energy intake may be affected ... eating rate may impair the relationship between the sensory signals ...
Cached Biology News:Testosterone in male songbirds may enhance desire to sing but not song quality 2Testosterone in male songbirds may enhance desire to sing but not song quality 3Meloidogyne mali: A new invasive plant parasitic nematode in Europe 2Slower-paced meal reduces hunger but affects calorie consumption differently 2Slower-paced meal reduces hunger but affects calorie consumption differently 3
Anti-Mouse C-10, Biotin (Polyclonal) (rabbit IgG)...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
... Antibody is used to detect the appearance ... of infected cells as early as 8-24 ... the FastPlax Titer Kit, which allows determination ... The FastPlax Antibody can also ...
Alexa Fluor 647 anti-mouse IL-12 (Interleukin-12) / IL-23 (Interleukin-23) p40 25 ug...
Biology Products: